NetraMark Shares Jump 9% as AI Platform Gains Traction in Clinical Trials

NetraMark shares jump 9% to €0.60 as its explainable AI platform gains traction in pharma, targeting SaaS revenue and Alzheimer's trial breakthroughs.

NetraMark’s stock surged nine percent on Monday to €0.60, as investors responded to mounting evidence that the company’s artificial intelligence platform is carving out a valuable niche in pharmaceutical research. The Canadian firm, which uses machine learning to optimise patient selection in drug trials, is now working to convert pilot partnerships into broader commercial agreements.

The company’s technology, branded NetraAI, sifts through complex clinical datasets to identify patient subgroups most likely to respond to experimental therapies. In Alzheimer’s studies, the platform has already pinpointed specific cohorts that showed strong treatment responses — data that drugmakers prize for reducing the risk of costly late-stage trial failures. This capability is particularly relevant as regulators push for greater transparency in medical AI, a challenge NetraMark addresses by relying on explainable algorithms rather than opaque black-box models.

Management is betting that recurring software-as-a-service revenue will replace the lumpy income from one-off project fees, a shift that institutional investors view as a key metric for long-term valuation. The strategy received a tailwind in April when a US executive order aimed at accelerating therapies for severe mental health conditions opened the door for faster approvals of psychedelic-based treatments. NetraMark’s analytics are well-suited to these complex trials, where precise patient stratification can make the difference between a failed study and a breakthrough.

Despite Monday’s rally, the shares remain under pressure. The stock has fallen roughly 11 percent since the start of the year and is still trading 44 percent below its 52-week high of €1.08. Over the past twelve months, the decline has been steeper at around 37 percent, though the current price is comfortably above the annual trough of €0.49.

The next major catalyst comes in May 2026, when NetraMark reports second-quarter results. Those numbers will reveal whether the spring’s new contracts are translating into tangible revenue growth. For now, the company’s fate hinges on winning over big biotech partners who can validate the platform at scale — a milestone that would mark a genuine turning point for the stock.